EAC 2019 Update in Allergy, Asthma and Immunology

May 30, 2019 to June 2, 2019

The EAC 2019 Update in Allergy, Asthma & Immunology meeting will provide learners with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology. Learners will not only gain insights with regard to selecting the best therapeutic alternative for each patient, but they will also have the opportunity to develop novel strategies designed to enhance therapeutic adherence through shared decision making. The format will incorporate problem based learning (PBL), uniquely designed to interface with lectures in context to the core issues relevant to the cases. By means of active discussion, learners will be challenged to formulate and justify medical decision making concerning advancements in the diagnosis and treatment strategies for patients. Topics of discussion will include updates in diagnosis and treatment of HAE, biologics for severe asthma, allergic skin diseases, advances in peanut allergy treatments and management of penicillin and other antibiotic allergies.
 

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity, participants should be able to:

--Describe the burden of illness attributable to allergic diseases.
--Define severe asthma and describe the major phenotypes
--Outline an approach to the use of biologics for allergic diseases
--Discuss therapeutic options for the management of peanut allergy
--Discuss advancements in the diagnosis and treatment of HAE
--Outline strategies to improve allergy immunotherapy efficacy and minimize adverse reactions

This activity is supported by independent educational grants from CSL Behring, DBV Technologies, Optinose, Pharming, Shire and Stallergenes Greer.

Additional information
Disclosure: 

Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all relevant financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no relevant financial relationships must also inform the learners that no relevant financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified conflicts of interest have been resolved.

David Bernstein, MD – Speaker

Speaker - ALK

Independent Contractor -ALK, GlaxoSmithKline, Merck, AstraZeneca, Biocryst, Adare, Glenmark, Leo, NeRRe, Novartis

Advisory Board – ALK, GlaxoSmithKline

Francisco Bonilla, MD – Speaker

Speaker - Shire

Don Bukstein, MD – Speaker

Speaker –AstraZeneca, Novartis, Genentech, ALK

William Corrao, MD – Planner, Moderator

Speaker - GlaxoSmithKline

Ray Davis, MD – Speaker

Consultant – ALK, AstraZeneca, Baxalta/Shire, Genentech, Shire Ophth Division, Novartis, Circassia

Speaker – DBV Technologies, ALK, AstraZeneca, Meda

Advisory Board - DBV Technologies

David Lang, MD – Speaker

Consultant – AstraZeneca

Speaker – ALK, AstraZeneca, Boehringer Ingelheim, Genentech, Teva, Novartis, Sanofi/Regeneron

Advisory Board – AstraZeneca

Independent Contractor – AstraZeneca

Author - AstraZeneca

Dennis Ledford, MD – Speaker

Consultant – AstraZeneca, Genentech

Speaker - ALK, Boehringer Ingelheim, Teva, Novartis, Sanofi/Regeneron, Genentech
Advisory Board –AstraZeneca

Independent Contractor – AstraZeneca

Data Safety Committee– Galderma 

Jay Lieberman, MD – Speaker

Consultant –Aimmune

Advisory Board – Aimmune, DBV Technologies, Aquestive,

Phil Lieberman, MD – Speaker

Consultant - Kaleo

John Oppenheimer, MD - Speaker

Consultant – AstraZeneca, Sanofi, Novartis, DBV Technologies

Advisory Board - GlaxoSmithKline

Anju Peters, MD – Speaker

Consultant – Sanofi/Regeneron, Optinose

Advisory Board - Sanofi/Regeneron, Optinose, ALK, Novartis

Independent Contractor - AstraZeneca

Stephen Peters, MD – Speaker

Advisory Board – AstraZeneca, Genentech, GlaxoSmithKline, Mylan, NIAID, Novartis, PRIME, Quintiles, Sanofi/Regeneron, Teva, Theravance,

Independent Contractor – AstraZeneca, Genentech, GlaxoSmithKline, Sanofi/Regeneron, Teva, Medimmune, Boehringer Ingelheim

Jay Portnoy, MD – Speaker

Speaker – Boehringer Ingelheim, Thermofisher

Consultant – Teva

Robert Settipane, MD – Planner/Moderator

Independent Contractor - AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Merck, Teva, Novartis, Syneos Health

Russell Settipane, MD – Planner/Moderator/Speaker/Reviewer

Speaker – Alk, AstraZeneca, Genentech, Pharming, Regeneron, Sanofi, Shire, Sunovion, Teva

Advisory Board - Alk, AstraZeneca, Genentech, Pharming, Regeneron, Sanofi, Teva

Independent Contractor – AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Merck, Novartis, Syneos Health, Teva

Stanley Szefler, MD – Speaker

Advisory Board – AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, Propeller Health

Julie Wang, MD – Speaker

Consultant –DBV Technologies

DMC Member – ALK

The following have no relevant financial relationships to disclose:

Joseph Bellanti, MD – Planner/ Speaker

William Greisner, III, MD – Planner/Moderator/Reviewer

David Khan, MD - Speaker

Neill Peters, MD - Speaker

Ginny Loiselle – Staff

Melinda Rathkopf, MD - Speaker

Marcus Shaker, MD - Speaker

Michael Slaughter, MD – Planner/Moderator

Kelli Wilson – Planner/Board Member

Course summary
Available credit: 
  • 15.50 AMA PRA Category 1 Credit™
  • 15.50 Attendance
Course opens: 
05/30/2019
Course expires: 
06/02/2021
Event starts: 
05/30/2019 - 4:30pm
Event ends: 
06/02/2019 - 10:30am
Cost:
$0.00
Rating: 
0

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Eastern Allergy Conference (EAC).  The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of  15.50 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 15.50 AMA PRA Category 1 Credit™
  • 15.50 Attendance

Accreditation Period

Course opens: 
05/30/2019
Course expires: 
06/02/2021

Price

Cost:
$0.00
Please login or create an account to take this course.